This post was originally published on this site
It said it would deliver the vaccine to Biomedical Advanced Research and Development Authority (BARDA) on a not-for-profit basis to be used after approval or emergency use authorization by the U.S. Food and Drug Administration (FDA).
The U.S. government may also purchase an additional 200 million doses under a subsequent agreement, it said.
The latest deal comes after BARDA agreed to provide $1 billion for J&J to build manufacturing capacity to make more than 1 billion doses of its experimental vaccine.
This is J&J’s first deal to supply its investigational vaccine to a country. Talks are underway with the European Union, but no deal has yet been agreed.
J&J’s investigational vaccine is currently being tested on healthy volunteers in the United States and Belgium in an early stage study.
There are currently no approved vaccines for COVID-19, and more than 20 are in clinical trials.
